A map to study exRNA, a novel form of cell-to-cell communication
Ribonucleic acid or RNA, one type of genetic material that is present inside all living cells, is mostly known to act as a messenger carrying instructions encoded in the DNA for the synthesis of proteins. However, in recent years research has shown that RNA not only exists inside cells, but also is exported from cells as extracellular RNA (exRNA) and plays a role in cell-to-cell communication.
“ExRNAs exist in bodily fluids outside of cells where they can associate with a variety of carriers including RNA binding proteins (RBPs), but the cargo and distribution of RBPs across biofluids is largely unknown,” said co-corresponding author, Dr. Aleksandar Milosavljevic, professor and Henry and Emma Meyer Chair in Molecular Genetics at Baylor. He also is the director of the Graduate Program in Quantitative & Computational Biosciences and a member of the Dan L Duncan Comprehensive Cancer Center at Baylor. The Milosavljevic Lab is the host of the exRNA Atlas, the data management and resource repository of the Extracellular RNA Communication Consortium, an NIH Common Fund project exploring the biology of exRNA.
Our goal in this study was to fill a major gap in knowledge regarding the cargo and distribution of RBPs across several biofluids. Understanding the role of RBPs as carriers of exRNA opens a new road toward understanding its biology and provides new opportunities for the development of exRBP/exRNA liquid biopsy biomarkers,” said coauthor Robert Fullem, a graduate student in the Milosavljevic lab.
Filling this gap involved an international collaboration led by the Milosavljevic Lab and the Bogdan Mateescu laboratory at the ETH Zürich and University of Zürich. Together, they developed a new powerful resource, a map to study exRNA. The study, published in the journal Cell Genomics, lays the foundation to examine how exRNA and its carrier proteins found in bodily fluids function in a healthy as well as a diseased setting.
The researchers applied computational analyses to identify exRBPs in plasma, serum, saliva, urine and cerebrospinal fluid. The computational predictions were validated experimentally at about 80% in both plasma and cell cultures in the lab, suggesting high specificity for the computational method.
With this information, we developed a map of candidate exRBPs and their exRNA cargo in bodily fluids expanding the landscape of potential biomarkers that can now be studied in liquid biopsies and used to track normal and disease processes, potentially providing a means to accurately implement early detection and monitor disease processes,” Milosavljevic said.
We present this map as a resource available at no cost to the scientific community.”
Other contributors to this work include co-first authors Emily L. LaPlante and Alessandra Stürchler, David Chen, Anne C. Starner, Emmanuel Esquivel, Eric Alsop, Andrew R. Jackson, Ionita Ghiran, Getulio Pereira, Joel Rozowsky, Justin Chang, Mark Gerstein, Roger P. Alexander, Matthew E. Roth, Jeffrey Franklin, Robert Coffey, Robert L. Raffai, Isabelle M. Mansuy, Stavros Stavrakis, Andrew deMello, Louise C. Laurent, Yi-Ting Wang, Chia-Feng Tsai, Tao Liu, Jennifer Jones, Kendall Van Keuren-Jensen and Eric Van Nostrand. See the publication for a complete list of the institutions involved in this work.
This publication was supported in part by the NIH Common Fund (1UG3TR002881-01, 1U54DA036134-01,1U54DA049098-01, 1U54DA049098-01S1, 1UH3TR002881, OT2OD030547-01S1 and 5UG3TR002881-02). Further support was provided by CPRIT Scholar in Cancer Research grants RR200040, 4UH3CA241703-03, and a Swiss National Center of Competence (NCCR) in Research RNA & Disease grant.
